SenzaGen develops, performs and sells state-of-the-art non-animal tests for assessing a substance’s allergenicity. The GARD®test method combines genomic data from human cells with machine learning for a unique capability to assess whether a chemical could cause allergic reactions on the skin or in the respiratory tract. With excellent predictivity, GARD®meets needs in several industries and helps companies develop, produce and deliver safer and more sustainable products.
SenzaGen’s vision is to replace animal testing with best-in-class in vitro technology, establish a new industry standard and contribute to safer products in society.
SenzaGen’s mission is to develop and offer the best alternatives to animal tests.